COVID-19大流行对瑞典炎症性关节病患者的影响:从感染严重程度到对诊疗服务的影响
基于瑞典全国多登记库队列研究,2020年115 317例炎症性关节病患者COVID-19住院和死亡风险略高于普通人群(调整HR分别为1.33和1.23)。生物/靶向合成DMARD总体未增加住院或死亡风险,但JAK抑制剂存在潜在信号;大流行期间炎症性关节病发病率、风湿科就诊和传统合成DMARD配药下降。
要点
- 炎症性关节病患者COVID-19住院调整HR 1.33(95%CI 1.23-1.43),死亡调整HR 1.23(95%CI 1.08-1.40)。
- 生物/靶向合成DMARD总体未增加COVID-19住院或死亡风险,JAK抑制剂存在潜在信号。
- 大流行期间炎症性关节病发病率下降7%,风湿科就诊下降16%,传统合成DMARD配药下降8.5%。
核心结论
- 炎症性关节病患者发生严重COVID-19结局的风险增加,部分可能由关节病以外的医疗状况解释。
- SARS-CoV-2大流行对风湿科诊疗服务产生了可测量的影响,其未来影响有待评估。
研究设计与样本
- 全国多登记库链接的队列研究设计,每年定义2015-2020年炎症性关节病及DMARD使用。
- 2020年共纳入115 317例炎症性关节病患者,评估COVID-19住院或死亡的绝对与相对风险。
- 同时评估炎症性关节病发病率、风湿科就诊、DMARD使用及部分合并症发病率。
主要发现
- 两波疫情期间COVID-19住院和死亡的粗风险分别为0.94%和0.33%,两波间相似。
- 与普通人群相比,COVID-19住院调整HR 1.33(95%CI 1.23-1.43),死亡调整HR 1.23(95%CI 1.08-1.40)。
- 生物/靶向合成DMARD总体未增加COVID-19相关住院或死亡风险,但JAK抑制剂存在潜在信号。
- 大流行期间炎症性关节病发病率下降7%,风湿科就诊下降16%。
- 与既往年份相比,生物/靶向合成DMARD配药增加6.5%,传统合成DMARD配药下降8.5%,新发合并症减少,但部分变化属于潜在长期趋势。
关键数值与推荐
- COVID-19住院粗风险0.94%,死亡粗风险0.33%(2020年115 317例炎症性关节病患者,两波疫情合计)。
- COVID-19住院调整HR 1.33(95%CI 1.23-1.43),死亡调整HR 1.23(95%CI 1.08-1.40),均与普通人群比较。
- 炎症性关节病发病率下降7%,风湿科就诊下降16%。
- 生物/靶向合成DMARD配药增加6.5%,传统合成DMARD配药下降8.5%(与既往年份比较)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare risks for COVID-19-related outcomes in inflammatory joint diseases (IJDs) and across disease-modifying antirheumatic drugs (DMARDs) during the first two waves of the pandemic and to assess effects of the pandemic on rheumatology care provision. METHODS: Through nationwide multiregister linkages and cohort study design, we defined IJD and DMARD use annually in 2015-2020. We assessed absolute and relative risks of hospitalisation or death listing COVID-19. We also assessed the incidence of IJD and among individuals with IJD, rheumatologist visits, DMARD use and incidence of selected comorbidities. RESULTS: Based on 115 317 patients with IJD in 2020, crude risks of hospitalisation and death listing COVID-19 (0.94% and 0.33% across both waves, respectively) were similar during both waves (adjusted HR versus the general population 1.33, 95% CI 1.23 to 1.43, for hospitalisation listing COVID-19; 1.23, 95% CI 1.08 to 1.40 for death listing COVID-19). Overall, biological disease-modifying antirheumatic drugs (bDMARDs)/targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) did not increase risks of COVID-19 related hospitalisation (with the exception of a potential signal for JAK inhibitors) or death. During the pandemic, decreases were observed for IJD incidence (-7%), visits to rheumatology units (-16%), DMARD dispensations (+6.5% for bDMARD/tsDMARDs and -8.5% for conventional synthetic DMARDs compared with previous years) and for new comorbid conditions, but several of these changes were part of underlying secular trends. CONCLUSIONS: Patients with IJD are at increased risk of serious COVID-19 outcomes, which may partially be explained by medical conditions other than IJD per se. The SARS-CoV-2 pandemic has exerted measurable effects on aspects of rheumatology care provision demonstrated, the future impact of which will need to be assessed.
引用
- Bower H, Frisell T, di Giuseppe D, et al. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021. PMID: 34880127. doi:10.1136/rmdopen-2021-001987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。